Addyi is a female libido drug, developed by Sprout Pharmaceuticals. It is the first and only FDA-approved non-hormonal pill for Hypoactive Sexual Desire Disorder (HSDD).
Addyi® (flibanserin) tablets is a prescription medicine used to treat Hypoactive (low) Sexual Desire Disorder (HSDD) in women who have not gone through menopause.
Sprout was founded in 2011 and is based in Raleigh, North Carolina. Sprout Pharmaceuticals was acquired by Valeant for $1B in 2015. Two years later, the company's CEO Cindy Eckert and her shareholders re-acquired Sprout.
Sprout Pharmaceuticals is committed to supporting research to advance the understanding of their products in new and innovative ways. At the core of this commitment is the desire to serve the needs of each and every patient who use our products.
Sprout Pharmaceuticals has raised a total of $45.5M in funding to date.
